Plasma therapy to treat COVID-19 patients under clinical trial in UAE

The treatment takes antibody-rich plasma from recovered coronavirus patients and injected into people who have severe cases of COVID-19, the disease caused by the virus. (Shutterstock)
Short Url
Updated 12 April 2020
Follow

Plasma therapy to treat COVID-19 patients under clinical trial in UAE

  • The UAE says it is also looking at potential drug treatments
  • There has been an increase in testing in recent weeks to detect more cases

DUBAI: The UAE is carrying out clinical trials of plasma therapy to treat COVID-19 patients, state news agency WAM reported on Sunday.

The treatment takes antibody-rich plasma from recovered coronavirus patients and injected into people who have severe cases of COVID-19, the disease caused by the virus.

The UAE says it is also looking at potential drug treatments such as chloroquine and hydroxychloroquine in efforts to treat patients.

“Some preliminary studies have shown the effectiveness of drugs such as chloroquine and hydroxychloroquine in COVID-19 treatment. These are drugs used in the country, and their effectiveness, as well as that of other antiviral drugs, is being continuously monitored,” the official spokesperson of the UAE health sector, Farida Al-Hosani, said.

Hosani said that there has been an increase in testing in recent weeks to detect more cases, limit the spread of the virus, and isolate those who came in contact with patients.

The government announced that 170 people had recovered from COVID-19 after receiving the necessary care, bringing the total number of recoveries to 588. Following additional testing of over 20,000 people in the past few days, 376 individuals were confirmed positive, bringing the total number of cases to 3,736.


Syria Kurds chief says ‘all efforts’ being made to salvage deal with Damascus

Updated 25 December 2025
Follow

Syria Kurds chief says ‘all efforts’ being made to salvage deal with Damascus

  • Abdi said the Syrian Democratic Forces (SDF), the Kurds’ de facto army, remained committed to the deal
  • The two sides were working toward “mutual understanding” on military integration and counter-terrorism

DAMASCUS: Syrian Kurdish leader Mazloum Abdi said Thursday that “all efforts” were being made to prevent the collapse of talks on an agreement with Damascus to integrate his forces into the central government.
The remarks came days after Aleppo saw deadly clashes between the two sides before their respective leaders ordered a ceasefire.
In March, Abdi signed a deal with Syrian President Ahmed Al-Sharaa to merge the Kurds’ semi-autonomous administration into the government by year’s end, but differences have held up its implementation.
Abdi said the Syrian Democratic Forces (SDF), the Kurds’ de facto army, remained committed to the deal, adding in a statement that the two sides were working toward “mutual understanding” on military integration and counter-terrorism, and pledging further meetings with Damascus.
Downplaying the year-end deadline, he said the deal “did not specify a time limit for its ending or for the return to military solutions.”
He added that “all efforts are being made to prevent the collapse of this process” and that he considered failure unlikely.
Abdi also repeated the SDF’s demand for decentralization, which has been rejected by Syria’s Islamist authorities, who took power after ousting longtime ruler Bashar Assad last year.
Turkiye, an important ally of Syria’s new leaders, sees the presence of Kurdish forces on its border as a security threat.
In Damascus this week, Turkish Foreign Minister Hakan Fidan stressed the importance of the Kurds’ integration, having warned the week before that patience with the SDF “is running out.”
The SDF control large swathes of the country’s oil-rich north and northeast, and with the support of a US-led international coalition, were integral to the territorial defeat of the Daesh group in Syria in 2019.
Syria last month joined the anti-IS coalition and has announced operations against the jihadist group in recent days.